ResMed (NYSE: RMD) reported earnings on April 25. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended March 31 (Q3), ResMed met expectations on revenues and beat slightly on earnings per share.

Compared to the prior-year quarter, revenue grew. Non-GAAP earnings per share grew significantly. GAAP earnings per share expanded significantly.

Margins grew across the board.

Revenue details
 ResMed logged revenue of $383.6 million. The 12 analysts polled by S&P Capital IQ expected sales of $386.8 million on the same basis. GAAP reported sales were 9.9% higher than the prior-year quarter's $349.1 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $0.59. The eight earnings estimates compiled by S&P Capital IQ averaged $0.58 per share. Non-GAAP EPS of $0.59 for Q3 were 28% higher than the prior-year quarter's $0.46 per share. GAAP EPS of $0.58 for Q3 were 32% higher than the prior-year quarter's $0.44 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 62.4%, 210 basis points better than the prior-year quarter. Operating margin was 25.1%, 290 basis points better than the prior-year quarter. Net margin was 22.1%, 360 basis points better than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
 Next quarter's average estimate for revenue is $409.0 million. On the bottom line, the average EPS estimate is $0.62.

Next year's average estimate for revenue is $1.51 billion. The average EPS estimate is $2.28.

Investor sentiment
 The stock has a three-star rating (out of five) at Motley Fool CAPS, with 194 members out of 210 rating the stock outperform, and 16 members rating it underperform. Among 65 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 61 give ResMed a green thumbs-up, and four give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on ResMed is outperform, with an average price target of $45.46.

Is ResMed the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.